Raffaele Colombo/LinkedIn
Nov 12, 2024, 01:22
Raffaele Colombo: Another PBD ADC discontinued
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared an article on X:
“Another PBD ADC (ADCT-601) discontinued.
ADCT-601 = anti-AXL mAb, site-specific conjugation via GlycoConnect, PBD payload.
The field continues to evolve: the total number of camptothecin ADCs has now surpassed auristatin ADCs!”
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development.
Authors: Raffaele Colombo, et al.
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 12:37
Aug 25, 2025, 12:23
Aug 25, 2025, 11:07
Aug 25, 2025, 09:45
Aug 25, 2025, 09:09